Supriya Lifescience Limited
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.
What Supriya files
- Investor Meet52
- Others44
- Updates18
- Board Meeting10
- Important10
- PPTs7
Supriya Lifescience shares its FY25-26 Annual Report and details for its 18th AGM. Shareholders can access reports via the company website and stock exchanges; direct weblinks are sent to those without registered emails.
Supriya Lifescience reports no new developments in the ongoing legal matter concerning its General Manager – Sales & Marketing. The case remains in court, awaiting further hearing. The company will update investors on any material changes.
Supriya Lifescience's Q1 FY27 revenue surged 30.8% YoY to 189.75 Cr, though PAT decreased to 24.04 Cr. Key growth drivers include strong export focus, new product commercialization in Anesthetic/ADHD segments, and commissioning of its Ambernath finished dosage facility.
Supriya Lifescience's GM of Sales & Marketing is in judicial custody following a customs investigation into a procedural lapse on an export transaction. The company believes this will not materially impact operations or financial position.
Supriya Lifescience's Board proposed a final dividend of Re. 1.00 (50%) per equity share for FY26. This dividend is taxable; shareholders must update details and submit documents for appropriate tax deduction.